Keyword: Vir Biotechnology
CSO Hayden will leave as Teva restructures, Bayer R&D reorg sees Moeller in and Busch out for Shire, Shire and Biogen get experienced CFOs.
Vir Biotech CEO Geroge Scangos has lined up infectious disease and immunology expert Skip Virgin from Washington University as its new R&D head.
Startup Vir Biotechnology, guided by former Biogen CEO George Scangos, is unveiling a multifaceted pipeline of treatments for infectious diseases.
Sanofi's diabetes head Guenter leaves for Almirall, FDA CDER's deputy director joins PhRMA as CMO, Biogen biosimilar unit head joins Scangos at Vir.
It didn’t take George Scangos very long to find a new role after leaving Biogen as he starts 2017 as the head of a new upstart: Vir Biotechnology.